Search

Your search keyword '"PEITSCH, Wiebke K."' showing total 345 results
Start Over Author "PEITSCH, Wiebke K."
345 results on '"PEITSCH, Wiebke K."'

3. Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most.

Author

Schaarschmidt, Marthe-Lisa, Kromer, Daniel, Wellmann, Phoebe, Peitsch, Wiebke K., and Kromer, Christian

Subjects
PATIENT preferences, ATOPIC dermatitis, ITCHING, QUALITY of life, KINASE inhibitors, REGRESSION analysis
Abstract

Background: The advent of biologics and janus kinase inhibitors has revolutionized treatment of atopic dermatitis (AD). Objective: To investigate preferences of patients with AD for attributes of currently approved systemic treatments and assess influencing factors. Methods: An online discrete choice experiment was conducted in patients with AD throughout Germany to analyze preferences for outcome (probability of (almost) clear skin at week 16, probability of significant itch improvement, time to onset of itch relief and type of side effects) and process attributes (application method and frequency of laboratory tests). Results: Participants (n=182, 75.3% female) considered side effects (Relative Importance Score (RIS): 31.2), (almost) clear skin (RIS: 24.2) and probability of itch improvement (RIS: 16.0) most important. Application method (RIS: 14.4), time to onset of itch relief (RIS: 7.4) and frequency of laboratory tests (RIS: 6.8) were less relevant. Preferences were significantly influenced by sex, age, psychiatric comorbidity, current therapy and health-related quality of life according to multivariate regression analysis. Conclusions: Participants attached great importance to safety and symptom control. However, preferences were also dependent on individual characteristics, underscoring the importance of personal counseling. Conjoined with medical considerations, patients’ preferences have fundamental impact on shared decisions for treatment of AD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Juxtanuclear Drebrin-Enriched Zone

Author

Ludwig-Peitsch, Wiebke K., COHEN, IRUN R., Series editor, LAJTHA, ABEL, Series editor, LAMBRIS, JOHN D., Series editor, PAOLETTI, RODOLFO, Series editor, REZAEI, NIMA, Series editor, Shirao, Tomoaki, editor, and Sekino, Yuko, editor

Published
2017
Full Text
View/download PDF

8. Drebrin in Renal Glomeruli

Author

Ludwig-Peitsch, Wiebke K., COHEN, IRUN R., Series editor, LAJTHA, ABEL, Series editor, LAMBRIS, JOHN D., Series editor, PAOLETTI, RODOLFO, Series editor, REZAEI, NIMA, Series editor, Shirao, Tomoaki, editor, and Sekino, Yuko, editor

Published
2017
Full Text
View/download PDF

9. Drebrin at Junctional Plaques

Author

Ludwig-Peitsch, Wiebke K., COHEN, IRUN R., Series editor, LAJTHA, ABEL, Series editor, LAMBRIS, JOHN D., Series editor, PAOLETTI, RODOLFO, Series editor, REZAEI, NIMA, Series editor, Shirao, Tomoaki, editor, and Sekino, Yuko, editor

Published
2017
Full Text
View/download PDF

16. Real‐world outcomes using PD ‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Author

Schumann, Katharina, primary, Mauch, Cornelia, additional, Klespe, Kai‐Christian, additional, Loquai, Carmen, additional, Nikfarjam, Ulrike, additional, Schlaak, Max, additional, Akçetin, Larissa, additional, Kölblinger, Peter, additional, Hoellwerth, Magdalena, additional, Meissner, Markus, additional, Mengi, Guelcin, additional, Braun, Andreas Dominik, additional, Mengoni, Miriam, additional, Dummer, Reinhard, additional, Mangana, Joanna, additional, Sindrilaru, Mihaela‐Anca, additional, Radmann, Dan, additional, Hafner, Christine, additional, Freund, Johann, additional, Rappersberger, Klemens, additional, Weihsengruber, Felix, additional, Meiss, Frank, additional, Reinhardt, Lydia, additional, Meier, Friedegund, additional, Rainer, Barbara, additional, Richtig, Erika, additional, Ressler, Julia Maria, additional, Höller, Christoph, additional, Eigentler, Thomas, additional, Amaral, Teresa, additional, Peitsch, Wiebke K., additional, Hillen, Uwe, additional, Harth, Wolfgang, additional, Ziller, Fabian, additional, Schatton, Kerstin, additional, Gambichler, Thilo, additional, Susok, Laura, additional, Maul, Lara Valeska, additional, Läubli, Heinz, additional, Debus, Dirk, additional, Weishaupt, Carsten, additional, Börger, Sevil, additional, Sievers, Katharina, additional, Haferkamp, Sebastian, additional, Zenderowski, Veronika, additional, Nguyen, Van Anh, additional, Wanner, Marina, additional, Gutzmer, Ralf, additional, Terheyden, Patrick, additional, Kähler, Katharina, additional, Emmert, Steffen, additional, Thiem, Alexander, additional, Sachse, Michael, additional, Gercken‐Riedel, Silke, additional, Kaune, Kjell Matthias, additional, Thoms, Kai‐Martin, additional, Heinzerling, Lucie, additional, Heppt, Markus Vincent, additional, Tratzmiller, Sabine, additional, Hoetzenecker, Wolfram, additional, Öllinger, Angela, additional, Steiner, Andreas, additional, Peinhaupt, Tobias, additional, Podda, Maurizio, additional, Schmid, Sabine, additional, Wollina, Uwe, additional, Biedermann, Tilo, additional, and Posch, Christian, additional

Published
2022
Full Text
View/download PDF

17. Patientenpräferenzen bei Hidradenitis suppurativa (APProach‐HS): ein “Discrete‐Choice”‐Experiment

Author

Faverio, Kristin, primary, Peitsch, Wiebke K., additional, Görig, Tatiana, additional, Schneider‐Burrus, Sylke, additional, Benzel, Friderike, additional, Goebeler, Matthias, additional, Schummer, Patrick, additional, Badran, Alaa, additional, Schaarschmidt, Marthe‐Lisa, additional, Harth, Wolfgang, additional, Mössner, Rotraut, additional, and Kromer, Christian, additional

Published
2022
Full Text
View/download PDF

18. Patient Preferences in Hidradenitis Suppurativa (APProach‐HS): a discrete choice experiment

Author

Faverio, Kristin, primary, Peitsch, Wiebke K., additional, Görig, Tatiana, additional, Schneider‐Burrus, Sylke, additional, Benzel, Friderike, additional, Goebeler, Matthias, additional, Schummer, Patrick, additional, Badran, Alaa, additional, Schaarschmidt, Marthe‐Lisa, additional, Harth, Wolfgang, additional, Mössner, Rotraut, additional, and Kromer, Christian, additional

Published
2022
Full Text
View/download PDF

20. Real world outcomes using PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Author

Schumann, Katharina, Mauch, Cornelia, Klespe, Kai‐Christian, Loquai, Carmen, Nikfarjam, Ulrike, Schlaak, Max, Akçetin, Larissa, Kölblinger, Peter, Hoellwerth, Magdalena, Meissner, Markus, Mengi, Guelcin, Braun, Andreas Dominik, Mengoni, Miriam, Dummer, Reinhard, Mangana, Joanna, Sindrilaru, Mihaela‐Anca, Radmann, Dan, Hafner, Christine, Freund, Johann, Rappersberger, Klemens, Weihsengruber, Felix, Meiss, Frank, Reinhardt, Lydia, Meier, Friedegund, Rainer, Barbara, Richtig, Erika, Ressler, Julia Maria, Höller, Christoph, Eigentler, Thomas, Amaral, Teresa, Peitsch, Wiebke K., Hillen, Uwe, Harth, Wolfgang, Ziller, Fabian, Schatton, Kerstin, Gambichler, Thilo, Susok, Laura, Maul, Lara Valeska, Läubli, Heinz, Debus, Dirk, Weishaupt, Carsten, Börger, Sevil, Sievers, Katharina, Haferkamp, Sebastian, Zenderowski, Veronika, Nguyen, Van Anh, Wanner, Marina, Gutzmer, Ralf, Terheyden, Patrick, Kähler, Katharina, Emmert, Steffen, Thiem, Alexander, Sachse, Michael, Gercken‐Riedel, Silke, Kaune, Kjell Matthias, Thoms, Kai‐Martin, Heinzerling, Lucie, Heppt, Markus Vincent, Tratzmiller, Sabine, Hoetzenecker, Wolfram, Öllinger, Angela, Steiner, Andreas, Peinhaupt, Tobias, Podda, Maurizio, Schmid, Sabine, Wollina, Uwe, Biedermann, Tilo, and Posch, Christian

Subjects
ddc:610
Abstract

Background Programmed death‐1 (PD‐1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high‐risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real‐world study reports on clinical outcomes of modern adjuvant melanoma treatment in specialized skin cancer centers in Germany, Austria and Switzerland. Methods Multicenter, retrospective study investigating stage III–IV melanoma patients receiving adjuvant nivolumab (NIV), pembrolizumab (PEM) or dabrafenib + trametinib (D + T) between 1/2017 and 10/2021. The primary endpoint was 12‐month recurrence‐free survival (RFS). Further analyses included descriptive and correlative statistics, and a multivariate linear‐regression machine learning model to assess the risk of early melanoma recurrence. Results In total, 1198 patients from 39 skin cancer centers from Germany, Austria and Switzerland were analysed. The vast majority received anti PD‐1 therapies (n = 1003). Twelve‐month RFS for anti PD‐1 and BRAF + MEK inhibitor‐treated patients were 78.1% and 86.5%, respectively (hazard ratio [HR] 1.998 [95% CI 1.335–2.991]; p = 0.001). There was no statistically significant difference in overall survival (OS) in anti PD‐1 (95.8%) and BRAF + MEK inhibitor (96.9%) treated patients (p > 0.05) during the median follow‐up of 17 months. Data indicates that anti PD‐1 treated patients who develop immune‐related adverse events (irAEs) have lower recurrence rates compared to patients with no irAEs (HR 0.578 [95% CI 0.443–0.754], p = 0.001). BRAF mutation status did not affect overall efficacy of anti PD‐1 treatment (p > 0.05). In both, anti PD‐1 and BRAF + MEK inhibitor treated cohorts, data did not show any difference in 12‐month RFS and 12‐month OS comparing patients receiving total lymph node dissection (TLND) versus sentinel lymph node biopsy only (p > 0.05). The recurrence prediction model reached high specificity but only low sensitivity with an AUC = 0.65. No new safety signals were detected. Overall, recorded numbers and severity of adverse events were lower than reported in pivotal phase III trials. Conclusions Despite recent advances in adjuvant melanoma treatment, early recurrence remains a significant clinical challenge. This study shows that TLND does not reduce the risk of early melanoma recurrence and should only be considered in selected patients. Data further highlight that variables collected during clinical routine are unlikely to allow for a clinically relevant prediction of individual recurrence risk.

Published
2022

21. Melanomversorgung während eines Jahres Pandemie in Berlin: abnehmende Terminstornierungen trotz zunehmender Besorgnis über COVID‐19

Author

Micek, Aleksandra, primary, Diehl, Katharina, additional, Teuscher, Miriam, additional, Schaarschmidt, Marthe‐Lisa, additional, Sasama, Bianca, additional, Ohletz, Jan, additional, Burbach, Guido, additional, Kiecker, Felix, additional, Hillen, Uwe, additional, Harth, Wolfgang, additional, and Peitsch, Wiebke K., additional

Published
2022
Full Text
View/download PDF

22. Melanoma care during one year pandemic in Berlin: decreasing appointment cancellations despite increasing COVID‐19 concern

Author

Micek, Aleksandra, primary, Diehl, Katharina, additional, Teuscher, Miriam, additional, Schaarschmidt, Marthe‐Lisa, additional, Sasama, Bianca, additional, Ohletz, Jan, additional, Burbach, Guido, additional, Kiecker, Felix, additional, Hillen, Uwe, additional, Harth, Wolfgang, additional, and Peitsch, Wiebke K., additional

Published
2022
Full Text
View/download PDF

27. Ein Teenager mit Blasen und Krusten

Author

Ludwig‐Peitsch, Wiebke K., primary, Zahn, Axel, additional, Barkibin, Payman, additional, Guski, Silja, additional, Schmidt, Enno, additional, and Girschick, Hermann J., additional

Published
2022
Full Text
View/download PDF

29. A teenager with blisters and crusts

Author

Peitsch, Wiebke K., primary, Zahn, Axel, additional, Barkibin, Payman, additional, Guski, Silja, additional, Schmidt, Enno, additional, and Girschick, Hermann J., additional

Published
2022
Full Text
View/download PDF

30. Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

Author

Schumann, Katharina, Mauch, Cornelia, Klespe, Kai-Christian, Loquai, Carmen, Nikfarjam, Ulrike, Schlaak, Max, Akçetin, Larissa, Kölblinger, Peter, Hoellwerth, Magdalena, Meissner, Markus, Mengi, Guelcin, Braun, Andreas Dominik, Mengoni, Miriam, Dummer, Reinhard, Mangana, Joanna, Sindrilaru, Mihaela-Anca, Radmann, Dan, Hafner, Christine, Freund, Johann, Rappersberger, Klemens, Weihsengruber, Felix, Meiss, Frank, Reinhardt, Lydia, Meier, Friedegund, Rainer, Barbara, Richtig, Erika, Ressler, Julia Maria, Höller, Christoph, Eigentler, Thomas, Amaral, Teresa, Peitsch, Wiebke K., Hillen, Uwe, Harth, Wolfgang, Ziller, Fabian, Schatton, Kerstin, Gambichler, Thilo, Susok, Laura, Maul, Lara Valeska, Läubli, Heinz, Debus, Dirk, Weishaupt, Carsten, Börger, Sevil, Sievers, Katharina, Haferkamp, Sebastian, Zenderowski, Veronika, Nguyen, Van Anh, Wanner, Marina, Gutzmer, Ralf, Terheyden, Patrick, Kähler, Katharina, Emmert, Steffen, Thiem, Alexander, Sachse, Michael, Gercken-Riedel, Silke, Kaune, Kjell Matthias, Thoms, Kai-Martin, Heinzerling, Lucie, Heppt, Markus Vincent, Tratzmiller, Sabine, Hoetzenecker, Wolfram, Öllinger, Angela, Steiner, Andreas, Peinhaupt, Tobias, Podda, Maurizio, Schmid, Sabine, Wollina, Uwe, Biedermann, Tilo, and Posch, Christian

Subjects
IMMUNE CHECK POINT AND BRAF-MEK INHIBITORS IN MELANOMA [ORIGINAL ARTICLE, SPECIAL ISSUE ON MELANOMA], ddc
Published
2021

31. Unique and common TCR repertoire features of Ni2+‐, Co2+‐, and Pd2+‐specific human CD154 + CD4+ T cells.

Author

Riedel, Franziska, Aparicio‐Soto, Marina, Curato, Caterina, Münch, Lucas, Abbas, Amro, Thierse, Hermann‐Josef, Peitsch, Wiebke K., Luch, Andreas, and Siewert, Katherina

Subjects
T cells, MONONUCLEAR leukocytes, T cell receptors, CD4 antigen, IMMUNOLOGIC memory
Abstract

Background: Apart from Ni2+, Co2+, and Pd2+ ions commonly trigger T cell‐mediated allergic contact dermatitis. However, in vitro frequencies of metal‐specific T cells and the mechanisms of antigen recognition remain unclear. Methods: Here, we utilized a CD154 upregulation assay to quantify Ni2+‐, Co2+‐, and Pd2+‐specific CD4+ T cells in peripheral blood mononuclear cells (PBMC). Involved αβ T cell receptor (TCR) repertoires were analyzed by high‐throughput sequencing. Results: Peripheral blood mononuclear cells incubation with NiSO4, CoCl2, and PdCl2 increased frequencies of CD154 + CD4+ memory T cells that peaked at ~400 μM. Activation was TCR‐mediated as shown by the metal‐specific restimulation of T cell clones. Most abundant were Pd2+‐specific T cells (mean 3.5%, n = 19), followed by Co2+‐ and Ni2+‐specific cells (0.6%, n = 18 and 0.3%, n = 20) in both allergic and non‐allergic individuals. A strong overrepresentation of the gene segment TRAV9‐2 was unique for Ni2+‐specific TCR (28% of TCR) while Co2+ and Pd2+‐specific TCR favorably expressed TRAV2 (8%) and the TRBV4 gene segment family (21%), respectively. As a second, independent mechanism of metal ion recognition, all analyzed metal‐specific TCR showed a common overrepresentation of a histidine in the complementarity determining region 3 (CDR3; 15% of α‐chains, 34% of β‐chains). The positions of the CDR3 histidine among metal‐specific TCR mirrored those in random repertoires and were conserved among cross‐reactive clonotypes. Conclusions: Induced CD154 expression allows a fast and comprehensive detection of Ni2+‐, Co2+‐, and Pd2+‐specific CD4+ T cells. Distinct TCR repertoire features underlie the frequent activation and cross‐reactivity of human metal‐specific T cells. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population

Author

Hirose, Misa, Schilf, Paul, Benoit, Sandrine, Eming, Rüdiger, Gläser, Regine, Homey, Bernhard, Kunz, Manfred, Nebel, Almut, Peitsch, Wiebke K., Pföhler, Claudia, Sárdy, Miklós, Schreiber, Stefan, Zillikens, Detlef, Schmidt, Enno, Ibrahim, Saleh M., Däschlein, Georg, Goebeler, Matthias, Goetze, Steven, Günther, Claudia, Hadaschik, Eva, Hunzelmann, Nicolas, Kreuter, Alexander, Lippert, Undine, Sticherling, Michael, and Worm, Margitta

Published
2015
Full Text
View/download PDF

39. Additional file 1 of Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans

Author

Schwarm, Christian, Gola, Damian, Holtsche, Maike M., Dieterich, Anabelle, Bhandari, Anita, Freitag, Miriam, Nürnberg, Peter, Toliat, Mohammad, Lieb, Wolfgang, Wittig, Michael, Franke, André, Worm, Margitta, Sticherling, Michael, Ehrchen, Jan, Günther, Claudia, Gläser, Regine, Peitsch, Wiebke K., Sárdy, Miklós, Eming, Rüdiger, Hertl, Michael, Benoit, Sandrine, Goebeler, Matthias, Pföhler, Claudia, Kunz, Manfred, Kreuter, Alexander, Van Beek, Nina, Erdmann, Jeanette, Busch, Hauke, Zillikens, Detlef, Sadik, Christian D., Hirose, Misa, König, Inke R., Schmidt, Enno, and Ibrahim, Saleh M.

Abstract

Additional file 1. Materials and methods. References. Table 1: The age range of samples used in this study. Table 2: Sample numbers of the BP GWAS cohorts. Table 3: Distribution of posterior probabilities of imputed HLA alleles.

Published
2021
Full Text
View/download PDF

40. Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and-DRB1*07:01, in Germans

Author

Schwarm, Christian, Gola, Damian, Holtsche, Maike M., Dieterich, Anabelle, Bhandari, Anita, Freitag, Miriam, Nuernberg, Peter, Toliat, Mohammad, Lieb, Wolfgang, Wittig, Michael, Franke, Andre, Worm, Margitta, Sticherling, Michael, Ehrchen, Jan, Guenther, Claudia, Glaeser, Regine, Peitsch, Wiebke K., Sardy, Miklos, Eming, Ruediger, Hertl, Michael, Benoit, Sandrine, Goebeler, Matthias, Pfoehler, Claudia, Kunz, Manfred, Kreuter, Alexander, van Beek, Nina, Erdmann, Jeanette, Busch, Hauke, Zillikens, Detlef, Sadik, Christian D., Hirose, Misa, Koenig, Inke R., Schmidt, Enno, Ibrahim, Saleh M., Schwarm, Christian, Gola, Damian, Holtsche, Maike M., Dieterich, Anabelle, Bhandari, Anita, Freitag, Miriam, Nuernberg, Peter, Toliat, Mohammad, Lieb, Wolfgang, Wittig, Michael, Franke, Andre, Worm, Margitta, Sticherling, Michael, Ehrchen, Jan, Guenther, Claudia, Glaeser, Regine, Peitsch, Wiebke K., Sardy, Miklos, Eming, Ruediger, Hertl, Michael, Benoit, Sandrine, Goebeler, Matthias, Pfoehler, Claudia, Kunz, Manfred, Kreuter, Alexander, van Beek, Nina, Erdmann, Jeanette, Busch, Hauke, Zillikens, Detlef, Sadik, Christian D., Hirose, Misa, Koenig, Inke R., Schmidt, Enno, and Ibrahim, Saleh M.

Abstract

Bullous pemphigoid (BP) is the most common autoimmune skin blistering disease characterized by autoimmunity against the hemidesmosomal proteins BP180, type XVII collagen, and BP230. To elucidate the genetic basis of susceptibility to BP, we performed the first genome-wide association study (GWAS) in Germans. This GWAS was combined with HLA locus targeted sequencing in an additional independent BP cohort. The strongest association with BP in Germans tested in this study was observed in the two HLA loci, HLA-DQA1*05:05 and HLA-DRB1*07:01. Further studies with increased sample sizes and complex studies integrating multiple pathogenic drivers will be conducted.

Published
2021

47. Patientenpräferenzen für die Therapie fortgeschrittener Melanome: Einfluss von Komorbidität

Author

Weilandt, Juliane, primary, Diehl, Katharina, additional, Schaarschmidt, Marthe‐Lisa, additional, Kiecker, Felix, additional, Sasama, Bianca, additional, Pronk, Melanie, additional, Ohletz, Jan, additional, Könnecke, Andreas, additional, Müller, Verena, additional, Utikal, Jochen, additional, Hillen, Uwe, additional, Harth, Wolfgang, additional, and Peitsch, Wiebke K., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results